ALNYLAM PHARMACEUTICALS, INC. (ALNY) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US02043Q1076
ALNYLAM PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.71 bn USD |
| Gross profit | 3.04 bn USD |
| Operating income | 501.58 m USD |
| EBIT | 464.31 m USD |
| Net income | 313.75 m USD |
| Diluted EPS – continuing operations | 2.33 USD |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
More stocks
- Imperial Brands PLC (IMB.L)
- Cerebras Systems Inc. Class A Common Stock (CBRS)
- DSM-Firmenich AG (DSFIR.AS)
- Svenska Handelsbanken AB (SHB A.ST)
- Raymond James Financial (RJF)
- Ingersoll Rand (IR)
- Wanhua Chemical Group Co Ltd (600309.SS)
- Silicon Motion Technology Corp (SIMO)
- Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760.SZ)
- Reddit (RDDT)
- Seven & i Holdings Co Ltd (3382.T)
- Doosan Heavy Ind. & Const. (034020.KS)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.